Kimberly-Clark (KMB) Q2 2026 Prepared Remarks earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2026 Prepared Remarks earnings summary
4 Aug, 2026Executive summary
Achieved net sales of $4.2 billion in Q2 2026, up 0.6% year-over-year, with organic sales flat due to China social media disruption impacting diaper sales.
Adjusted operating profit rose 6.2% to $757 million, driven by gross productivity savings and one-time tariff refunds, despite headwinds from business exits and China disruption.
Adjusted EPS from continuing operations increased 10.4% to $1.80, supported by productivity gains and lower net interest expense.
Transformation initiatives advanced, including the Arbex joint venture with Suzano, Kenvue acquisition progress, and alternative natural fiber innovation.
Maintained strong brand momentum through innovation, marketing, and disciplined execution across key markets, especially in North America and Asia.
Financial highlights
Q2 2026 net sales were $4.2 billion (+0.6%); organic sales growth was -0.1% year-over-year.
Q2 adjusted operating profit was $757 million (+6.2%); adjusted gross margin was 38.8% (+190 bps).
Adjusted EPS from continuing operations was $1.80 (+10.4%); adjusted EPS attributable to the company was $2.12 (+10.4%).
Adjusted free cash flow for H1 2026 reached $1.1 billion, on pace for $2 billion for the full year.
Cash provided by operations in H1 was $1.7 billion; capital spending was $776 million; $843 million returned to shareholders via dividends.
Outlook and guidance
2026 organic sales growth expected to be ~100 bps below category average due to China disruption.
Adjusted operating profit projected to grow mid-single digits (constant currency); adjusted EPS from continuing operations to grow high single digits.
Adjusted EPS attributable expected to see a low single-digit decline (constant currency).
Free cash flow guidance maintained at ~$2 billion, with capital investments increasing to ~$1.3 billion.
The Kenvue acquisition is expected to close in H2 2026, subject to regulatory approvals.
Latest events from Kimberly-Clark
- Adjusted EPS rose 10.4% in Q2 2026, but China disruption led to a cautious outlook.KMB
Q2 2026 (Q&A)4 Aug 2026 - A $48.7B merger forms a global health leader, targeting $2.1B in synergies by 2029.KMB
M&A Announcement15 Jul 2026 - Q3 2024 delivered higher adjusted EPS and profit, reaffirming a strong 2024 outlook.KMB
Q3 20249 Jul 2026 - Premiumization, innovation, and efficiency drive double-digit shareholder returns and growth.KMB
Deutsche Bank dbAccess 2024 Global Consumer Conference8 Jul 2026 - 2025 targets volume-led growth, margin gains, and SG&A savings amid FX and divestiture headwinds.KMB
Q4 20248 Jul 2026 - Acquisition targets $1.9B in synergies, leveraging complementary strengths for growth.KMB
Morgan Stanley Global Consumer & Retail Conference 20258 Jul 2026 - Kenvue integration and innovation drive growth, productivity, and strong shareholder returns.KMB
23rd annual dbAccess Global Consumer Conference4 Jun 2026 - Strong growth, strategic acquisitions, and board elections defined the meeting's outcomes.KMB
AGM 202614 May 2026 - Transforming through innovation and acquisitions to build a global health and wellness leader.KMB
Barclays 18th Annual Americas Select Conference11 May 2026